Prevention, Remission or Delaying Type 2 Diabetes-Manifestation - Part 1

被引:1
|
作者
Landgraf, Ruediger [1 ,2 ,3 ,4 ,5 ]
机构
[1] LMU Munchen, Endokrinol Diabetol, Munich, Germany
[2] Deutsch Diabet Stiftung DDS, Dusseldorf, Germany
[3] Natl Steuergrp Entwicklung Natl Versorgungs Leitl, Martinsried, Germany
[4] Europaischen Diabet Gesell, Dusseldorf, Germany
[5] Deutsch Diabet Gesell, Berlin, Germany
关键词
LIFE-STYLE INTERVENTION; IMPAIRED GLUCOSE-TOLERANCE; FATTY LIVER-DISEASE; ALCOHOL-CONSUMPTION; FOLLOW-UP; RISK; METAANALYSIS; MORTALITY; INDIVIDUALS; ASSOCIATION;
D O I
10.1055/a-0872-6365
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Prevalence and incidence of diabetes and especially type 2 diabetes are worldwide growing dramatically. In 2019 around 463 million people suffered from diabetes with an enormous increase to 700 million up to the year 2045. Realistic estimates report even a doubling of the prevalence when considering the undiagnosed cases. In Germany the prevalence of diabetes is around 10 %, of undiagnosed cases 2 % and of people with prediabetes (impaired fasting glucose [IFG], impaired glucose tolerance [IGT] or both) 21 %. Diabetes and its complications account for at least 10-12 % of the total health expenditures in Germany. Prevention of type 2 diabetes together with other non-communicable diseases is therefore paramount to curtail this already existing health crisis. Drawing on the evidence from high quality randomized controlled trials, systematic reviews and meta-analyses lifestyle interventions are effective to prevent or delay the manifestation in high risk populations (i. e. prediabetes), which have to be identified by evaluated screening tools like the FINDRISK questionnaire and/or blood glucose parameters plus HbA 1c. The strategies for a successful prevention are attacking multiple risk factors for the development of type 2 diabetes (f. e. obesity/fatty liver, physical inactivity, unhealthy eating and drinking including alcohol as well as coffee and tea consumption, smoking, sleeping disorders, depression) with non-pharmacological behavioural prevention which will be discussed in this evidence-based review (part 1 of this CME paper). Part 2 deals with important aspects of a setting-based/environmental prevention. Both behavioural and environmental prevention strategies have closely work together in order to achieve long-lasting successes in diabetes prevention. © 2020 Georg Thieme Verlag. All rights reserved.
引用
收藏
页码:377 / 389
页数:13
相关论文
共 50 条
  • [1] Prevention, Remission, or Delaying Type-2-Diabetes-Manifestation - Part 2
    von Philipsborn, Peter
    Landgraf, Ruediger
    [J]. DIABETOLOGIE UND STOFFWECHSEL, 2020, 15 (06) : 457 - 469
  • [2] Development of Kidney Disease in Type-2-Diabetes; High Risk in Adolescent Diabetes-Manifestation
    Jecht, M.
    [J]. DIABETOLOGE, 2012, 8 (05): : 407 - 408
  • [3] Preventing, delaying, or masking type 2 diabetes with metformin in the Diabetes Prevention Program?
    Scheen, AJ
    [J]. DIABETES CARE, 2003, 26 (09) : 2701 - 2701
  • [4] Prediabetes remission for type 2 diabetes mellitus prevention
    Birkenfeld, Andreas L.
    Mohan, Viswanathan
    [J]. NATURE REVIEWS ENDOCRINOLOGY, 2024, 20 (08) : 441 - 442
  • [5] Intervention with Therapeutic Agents, Understanding the Path to Remission in Type 2 Diabetes Part 1
    Hao, Shuai
    Umpierrez, Guillermo E.
    Daley, Tanicia
    Vellanki, Priyathama
    [J]. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2023, 52 (01) : 27 - 38
  • [6] DATA FROM THE PERIOD OF CLINICAL MANIFESTATION AND SPONTANEOUS REMISSION OF TYPE-1 DIABETES
    VONDRA, K
    VOBORSKA, M
    HAMPL, R
    IVASKOVA, E
    MERHAUT, T
    PERUSICOVA, J
    SIMECKOVA, A
    STOLBA, P
    VRBIKOVA, J
    ZAMRAZIL, V
    [J]. DIABETOLOGIA, 1993, 36 : A170 - A170
  • [7] Preventing, delaying, or masking type 2 diabetes with metformin in the Diabetes Prevention Program? Response to Scheen and Buchanan
    Molitch, ME
    [J]. DIABETES CARE, 2003, 26 (09) : 2702 - 2703
  • [8] Remission of Type 2 Diabetes
    MacKay, Dylan
    Chan, Catherine
    Dasgupta, Kaberi
    Dominy, Cliff
    Gagner, Michel
    Jin, Susie
    Kim, James
    Little, Jonathan P.
    MacDonald, Barbara
    McInnes, Natalia
    Reichert, Sonja
    Bajaj, Harpreet S.
    Bajaj, Harpreet S.
    Gilbert, Jeremy
    Houlden, Robyn
    Kim, James
    MacDonald, Barbara
    MacKay, Dylan
    Mansell, Kerry
    Rabi, Doreen
    Senior, Peter
    Sherifali, Diana
    [J]. CANADIAN JOURNAL OF DIABETES, 2022, 46 (08) : 753 - +
  • [9] Intervention with Therapeutic Agents, Understanding the Path to Remission to Type 2 Diabetes Part 2
    Hao, Shuai
    Umpierrez, Guillermo E.
    Vellanki, Priyathama
    [J]. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2023, 52 (01) : 39 - 47
  • [10] Dorzagliatin for diabetes remission in type 2 diabetes
    Pavlicek, Vojtech
    [J]. DIABETOLOGIE, 2023, : 853 - 854